AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Positive Phase 2 data for emraclidine, expected by the end of 2024, could potentially unlock a multi-billion dollar market opportunity. AbbVie has been proactive in strengthening its portfolio and ...

AbbVie has been named a Top Socially Responsible ... Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. Indeed, studying ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

In the latest market close, AbbVie (ABBV) reached $170.30, with a -0.22% movement compared to the previous day. This change was narrower than the S&P 500's 0.29% loss on the day. At the same time ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

AbbVie holds a strong portfolio of marketed and ... Imbruvica's strong clinical data in several forms of blood cancer led to peak sales above $5 billion, but increasing competition has led to ...